PCMC
MLTX icon

Planning Capital Management Corporation’s MoonLake Immunotherapeutics MLTX Stock Holding History

Planning Capital Management Corporation’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$101 Hold
2
– – ﹤0.01% 721
2024
Q2 		$88 Buy
+2
New +$85 ﹤0.01% 668

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Planning Capital Management Corporation's MLTX Position: Q3 2024 in Review

Planning Capital Management Corporation held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2024 at 2 shares worth $101. The position accounts for ﹤0.01% of the portfolio, ranked #721.

Planning Capital Management Corporation first reported a position in MLTX in Q2 2024 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

  • Planning Capital Management Corporation held 2 shares of MoonLake Immunotherapeutics worth $101 as of Q3 2024.
  • Planning Capital Management Corporation left its MoonLake Immunotherapeutics share count unchanged in Q3 2024.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #721 holding.
  • Planning Capital Management Corporation first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.